Full-Time

High Performance Computing

HPC, Engineer

GenBio AI

GenBio AI

51-200 employees

AI-powered biological simulation for drug development

Compensation Overview

$170k - $260k/yr

Palo Alto, CA, USA

In Person

Category
AI & Machine Learning (1)
Required Skills
Kubernetes
Python
CUDA
Pytorch
Docker
AWS
Google Cloud Platform
Requirements
  • Master’s or Ph.D. degree in computer science, or a related field with a focus on High-Performance Computing, Distributed Systems, or Deep Learning
  • 2+ years proven experience in managing GPU clusters, including installation, configuration, and optimization
  • Strong expertise in distributed deep learning and parallel training techniques
  • Proficiency in popular deep learning frameworks like PyTorch, Megatron-LM, DeepSpeed, etc.
  • Programming skills in Python and experience with GPU-accelerated libraries (e.g., CUDA, cuDNN)
  • Knowledge of performance profiling and optimization tools for HPC and deep learning
  • Familiarity with resource management and scheduling systems (e.g., SLURM, Kubernetes)
  • Strong background in distributed systems, cloud computing (AWS, GCP), and containerization (Docker, Kubernetes)
Responsibilities
  • GPU Cluster Management: Design, deploy, and maintain high-performance GPU clusters, ensuring their stability, reliability, and scalability. Monitor and manage cluster resources to maximize utilization and efficiency.
  • Distributed/Parallel Training: Implement distributed computing techniques to enable parallel training of large deep learning models across multiple GPUs and nodes. Optimize data distribution and synchronization to achieve faster convergence and reduced training times.
  • Performance Optimization: Fine-tune GPU clusters and deep learning frameworks to achieve optimal performance for specific workloads. Identify and resolve performance bottlenecks through profiling and system analysis.
  • Deep Learning Framework Integration: Collaborate with data scientists and machine learning engineers to integrate distributed training capabilities into GenBio AI’s model development and deployment frameworks.
  • Scalability and Resource Management: Ensure that the GPU clusters can scale effectively to handle increasing computational demands. Develop resource management strategies to prioritize and allocate computing resources based on project requirements.
  • Troubleshooting and Support: Troubleshoot and resolve issues related to GPU clusters, distributed training, and performance anomalies. Provide technical support to users and resolve technical challenges efficiently.
  • Documentation: Create and maintain documentation related to GPU cluster configuration, distributed training workflows, and best practices to ensure knowledge sharing and seamless onboarding of new team members.

GenBio AI develops a digital organism called AIDO to simulate biological processes for drug development and personalized medicine. AIDO uses multiscale models to predict how molecules and cells behave, allowing researchers to test millions of potential treatments digitally to find the most effective options. Unlike traditional methods that rely heavily on physical trials, this platform provides actionable insights across multiple biological levels to improve vaccine safety and clinical diagnostics. The company's goal is to accelerate the creation of new medicines and minimize adverse reactions through partnerships with healthcare providers and research institutions.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Palo Alto, California

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 1 AIDO released six foundation models covering 796 species for rapid simulations.
  • Employee count reached 21-50 with $3.7M revenue and $11.8M valuation since 2024.
  • Global offices in California, Paris, and Abu Dhabi expand partnership opportunities.

What critics are saying

  • Insilico's 18 AI drugs in trials, including Phase 3 INS018_055, outpace AIDO in 6-12 months.
  • Recursion's 25 petabytes data and 200+ programs crush GenBio's unvalidated models in 12-18 months.
  • FDA January 2026 guidance mandates Phase 2 validation, halting AIDO adoption in 9-15 months.

What makes GenBio AI unique

  • AIDO simulates millions of treatments using multiscale foundation models from DNA to cells.
  • Dr. Ziv Bar-Joseph leads multiscale model integration for drug discovery since February 2025.
  • Dr. Emma Lundberg drives data strategy as Co-Founder since June 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-7%
PR Newswire
Jun 17th, 2025
Genbio Ai Welcomes Emma Lundberg As Co-Founder And Chief Scientific Advisor

PALO ALTO, Calif., June 17, 2025 /PRNewswire/ -- GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.In this role, Lundberg will focus on the development of GenBio AI's data strategy and other scientific initiatives, advancing its mission to build a generative digital organism

AI Magazine
Jun 17th, 2025
GenBio AI Welcomes Emma Lundberg as Co-Founder and Chief Scientific Advisor

PALO ALTO, Calif., June 17, 2025 /PRNewswire/ - GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.

GenBio AI
May 7th, 2025
How moscot Maps Cells Through Time, Space, and Modality by Dominik Klein

In this talk, Dominik Klein presents "Mapping cells through time and space with moscot" at the Foundation Models for Biology Seminar Series by GenBio AI.

PR Newswire
Feb 28th, 2025
Genbio Ai Expands Global Leadership With Ziv Bar-Joseph As Co-Founder And Chief Scientific Officer

PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited to announce that Dr. Ziv Bar-Joseph has joined as Co-founder and Chief Scientific Officer.In this role, Bar-Joseph will lead work focused on the integration and use of GenBio AI's multiscale foundation models, ensuring they drive real impact in drug discovery, medicine, and beyond. His leadership will be pivotal in helping the company transform AI applications in biology and push the boundaries of biological research.Bar-Joseph brings extensive expertise from Sanofi, a leading global pharmaceutical company. As the VP and Head of R&D Data and Computational Sciences, he led multidisciplinary teams in machine learning, computational biology, and data science to accelerate drug and vaccine discovery. He is also the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU), specializing in biological systems modeling, and AI applications in genomics and systems biology